Jan Paul de Boer

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Late cardiotoxicity after treatment for Hodgkin lymphoma

Berthe M.P. Aleman, Alexandra W. van den Belt‐Dusebout, Marie L. De Bruin et al. · Blood · 2006 · 766 citations · Full text

Medicine, Hematology, Oncology +12

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

Philippe Armand, Andreas Engert, Anas Younes et al. · Journal of Clinical Oncology · 2018 · 754 citations · Full text

Medicine, Hematology, Oncology +17

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

Michael Schaapveld, Berthe M.P. Aleman, Anna M. van Eggermond et al. · New England Journal of Medicine · 2015 · 626 citations · Full text

Medicine, Oncology, Cancer Control +13

Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients

Roberto N. Miranda, Tariq N. Aladily, H. Miles Prince et al. · Journal of Clinical Oncology · 2013 · 399 citations · Full text

Medicine, Oncology, Surgery +12